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Abstract: This study investigated the effect of decaffeinated green tea extract (dGTE), with or with-
out antioxidant nutrients, on fat oxidation, body composition and cardio-metabolic health measures 
in overweight individuals engaged in regular exercise. Twenty-seven participants (20 females, 7 
males; body mass: 77.5 ± 10.5 kg; body mass index: 27.4 ± 3.0 kg·m2; peak oxygen uptake (VO2peak): 
30.2 ± 5.8 mL·kg−1·min−1) were randomly assigned, in a double-blinded manner, either: dGTE (400 
mg·d−1 (−)-epigallocatechin−3-gallate (EGCG), n = 9); a novel dGTE+ (400 mg·d−1 EGCG, quercetin 
(50 mg·d−1) and α-lipoic acid (LA, 150 mg·d−1), n = 9); or placebo (PL, n = 9) for 8 weeks, whilst 
maintaining standardised, aerobic exercise. Fat oxidation (‘FATMAX’ and steady state exercise pro-
tocols), body composition, cardio-metabolic and blood measures (serum glucose, insulin, leptin, 
adiponectin, glycerol, free fatty acids, total cholesterol, high [HDL-c] and low-density lipoprotein 
cholesterol [LDL-c], triglycerides, liver enzymes and bilirubin) were assessed at baseline, week 4 
and 8. Following 8 weeks of dGTE+, maximal fat oxidation (MFO) significantly improved from 154.4 
± 20.6 to 224.6 ± 23.2 mg·min−1 (p = 0.009), along with a 22.5% increase in the exercise intensity at 
which fat oxidation was deemed negligible (FATMIN; 67.6 ± 3.6%VO2peak, p = 0.003). Steady state ex-
ercise substrate utilisation also improved for dGTE+ only, with respiratory exchange ratio reducing 
from 0.94 ± 0.01 at week 4, to 0.89 ± 0.01 at week 8 (p = 0.004). This corresponded with a significant 
increase in the contribution of fat to energy expenditure for dGTE+ from 21.0 ± 4.1% at week 4, to 
34.6 ± 4.7% at week 8 (p = 0.006). LDL-c was also lower (normalised fold change of −0.09 ± 0.06) for 
dGTE+ by week 8 (p = 0.038). No other significant effects were found in any group. Eight weeks of 
dGTE+ improved MFO and substrate utilisation during exercise, and lowered LDL-c. However, 
body composition and cardio-metabolic markers in healthy, overweight individuals who main-
tained regular physical activity were largely unaffected by dGTE.  
Keywords: green tea extract; fat oxidation; body fat; weight loss; exercise 
 
1. Introduction 
Green tea (GT) polyphenols have been widely investigated for their potential thera-
peutic health benefits from an antioxidant [1], anti-inflammatory [2,3], chemoprotective 
[4] and cardio-metabolic perspective [5–7]. The catechin content of GT, of which (−)-epi-
gallocatechin−3-gallate (EGCG) may account for up to 80% [8], may be primarily related 
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to adaptive mechanisms pertinent to health benefits. GT catechins may have specific ther-
mogenic effects through the inhibition of catechol-o-methyl transferase (COMT) and sub-
sequent catecholamine, cyclic adenosine monophosphate (cAMP) and lipolytic activity 
[9]. Consequently, these effects may enhance whole-body fat oxidation [10,11], and GT 
catechins may have important metabolic effects pertinent to reduced adipose tissue [12], 
improved body mass index (BMI) and/or body composition [10], and lowered circulating 
metabolites (e.g., low-density lipoprotein cholesterol (LDL-c) [13]). However, such mech-
anisms have also been challenged based on limited evidence from studies [14]. Regular 
consumption of GT catechins has also been proposed to exert ‘calorie-restriction-mimetic’ 
effects [15] over time, through modulated cell signalling (e.g., peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC1-α) , sirtuin 1 (SIRT1) and AMP-acti-
vated protein kinase (AMPK) pathways), influencing gene expression associated with mi-
tochondrial efficiency and fat oxidation [14], and is supported through emerging experi-
mental evidence [16]. 
In terms of fat oxidation, studies with administration of GT extract (GTE) for <7 days, 
providing between 270 and 375 mg·d−1 EGCG, have reported significant improvements in 
whole-body fat oxidation rates in untrained and overweight individuals both at rest 
[17,18], during exercise [18] and post-exercise [19], as well as increased 24 hour energy 
expenditure [11]. Elevated catecholamine and glycerol concentrations in response to acute 
EGCG supplementation [11,19] support mechanisms associated with COMT inhibition. 
However, this may, in part, be explained through the inclusion of high-intensity exercise 
invoking elevated catecholamine levels [19]. Surprisingly, the benefits observed in these 
studies occurred despite GTE consumption with food (which has been reported to reduce 
GTE bioavailability [20]), inferring that observed improvements in fat oxidation likely oc-
curred in response to pre-test fasted intake of GTE. Elsewhere, studies have reported no 
effect of short-term GTE supplementation on fat oxidation in trained individuals, with 
doses between 270 and 506 mg·d−1 EGCG [21,22], suggesting that GTE may be beneficial 
only for untrained/overweight individuals. 
In the longer term (>3 weeks), the effects of GTE supplementation on fat oxidation 
are equivocal. Low-dose GTE supplementation (68 mg·d−1 EGCG) for 3 weeks did not im-
prove fat oxidation during exercise in trained individuals [23,24], although improvements 
in cardio-metabolic and inflammatory metabolites (e.g., increased high-density lipopro-
tein cholesterol (HDL-c) [23], and reduced C-reactive protein [24]) were reported. A four-
week supplementation period of moderate-dose decaffeinated GTE (dGTE; 400 mg·d−1 
EGCG) significantly improved total fat oxidation rates during exercise, and reduced body 
fat percentage in one study [25], but not elsewhere, even when employing higher-dose 
dGTE (624 mg·d−1 EGCG [26]), with both studies involving healthy, lean males. 
With regards to cardio-metabolic risk factors, studies lasting 8-12 weeks also provide 
equivocal findings. Low-dose GTE supplementation (99 mg·d−1 GTE) for 8 weeks was not 
effective in improving body fat percentage, BMI, blood pressure, triglyceride and LDL-c 
levels over that obtained through introduction of aerobic training in overweight/obese, 
previously sedentary females [27]. Likewise, high-dose caffeinated GTE (1206.9 mg·d−1 
GTE; 595.8 mg·d−1 EGCG) for 12 weeks did not improve resting energy expenditure, body 
mass, BMI, waist to hip ratio (WHR) or fat mass over that explained through sustained 
inclusion of a low-energy diet in overweight woman [28]. In contrast, an eight-week GTE 
supplementation period (500 mg·d−1 GTE; ~225 mg·d−1 EGCG) significantly improved 
body mass, BMI, body fat percentage, visceral fat area (VFA) and adiponectin levels above 
that obtained through introduction of aerobic training in previously sedentary overweight 
women [29] and men [30]. Therefore, it is unclear whether GTE supplementation posi-
tively impacts on fat oxidation, body composition and cardio-metabolic risk factors in 
overweight individuals, particularly when unaccustomed diet or exercise interventions 
are introduced. 
In addition to the range of EGCG doses used, confounding factors such as GTE type 
and bioavailability may, in part, explain the varying findings observed. Only a handful of 
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studies have employed a dGTE formula [17,18,25,26], whereas positive benefits found 
elsewhere could be explained through the thermogenic effects of caffeine [11,19,29,30]. 
Whilst positive findings have been observed with a moderate EGCG dose (>300 mg·d−1), 
improving the bioavailability and effectiveness of GTE through standardised consump-
tion away from food [20] and/or inclusion of antioxidant nutrients (e.g., quercetin, α-lipoic 
acid (LA), curcumin [31–34]) may lead to enhanced fat oxidation, body composition, 
and/or cardio-metabolic risk factor improvement, particularly in overweight individuals. 
Indeed, precedent for the approach of combining GTE with quercetin or LA has previ-
ously been observed in animal models [35,36]. Elsewhere, use of a GT beverage with an-
tioxidant supplementation has been shown to enhance exercise capacity, glucose tolerance 
and body composition in older individuals [37]. However, there is a paucity of research 
confirming potential benefits of GTE compounds with human participants, despite novel 
combinations already being commercially available. Therefore, it is pertinent to investi-
gate the efficacy such compounds compared with GTE only use. 
Therefore, this study aimed to assess the longer-term impact of moderate dGTE sup-
plementation (with or without antioxidant nutrients) on fat oxidation, body composition 
and cardio-metabolic risk factors in overweight, but healthy individuals engaged in reg-
ular exercise. It was hypothesised that fat oxidation would be improved with dGTE (par-
ticularly when additional antioxidant nutrients are included), resulting in improved body 
composition and cardio-metabolic risk factors compared with placebo. 
2. Materials and Methods  
2.1. Ethical Approval and Study Participants 
This study was conducted in accordance with the Declaration of Helsinki (2013), and 
registered with ClinicalTrials.gov (Identifier: NCT04628624). Ethical approval was ob-
tained from the Faculty of Science and Technology Research Ethics Panel, Anglia Ruskin 
University (FST/FREP/17/703). Following a priori power calculation assessment 
(G*power3, Dusseldorf, Germany [38]; using α = 0.05; 1 − β = 0.80; based on observed fat 
oxidation data [18,25]), a minimum sample size of 7 (per group) was estimated. A total 
cohort of 44 participants volunteered for pre-screening selection, from which 13 partici-
pants did not meet the study inclusion criteria.  
Thirty-one participants were therefore invited to take part in the intervention study. 
However, 2 participants withdrew at week 4 for personal reasons, and data for 2 partici-
pants were excluded based on not meeting supplement adherence or testing criteria. 
Therefore, a total of 27 participants (20 females, 7 males; mean ± standard deviation (SD), 
age: 43 ± 8 years; body mass: 77.5 ± 10.0 kg; height: 1.68 ± 0.06 m; BMI: 27.4 ± 3.0 kg·m2; 
initial relative peak oxygen uptake (VO2peak): 30.2 ± 5.8 mL·kg−1·min−1) satisfactorily com-
pleted the intervention, with study power deemed sufficient based on a priori analysis. 
Participant characteristics for each intervention group are displayed in Table 1. All partic-
ipants provided written, informed consent, and satisfactorily completed a general health 
screen prior to study inclusion. 
Table 1. Baseline characteristics for intervention groups. 
 PL dGTE dGTE+ 
Variable (n = 9; 4 male, 5 female) 
(n = 9; 
2 male, 7 female) 
(n = 9; 
1 male, 8 female) 
Age (years) 35 ± 7 * 46 ± 5 47 ± 5 
Height (m) 1.71 ± 0.04 1.66 ± 0.06 1.67 ± 0.07 
Body mass (kg) 82.7 ± 13.0 74.3 ± 7.4 75.6 ± 9.4 
BMI (kg·m2) 28.2 ± 4.1 26.8 ± 2.4 27.1 ± 2.3 
Body fat (%) 32.0 ± 7.9 33.2 ± 6.6 36.3 ± 6.2 VO2peak (L·min−1) 2.5 ± 0.7 2.4 ± 0.6 2.1 ± 0.5 VO2peak (mL·kg−1·min−1) 30.3 ± 6.3 32.4 ± 5.2 27.8 ± 5.6 
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Data presented as the mean ± SD. PL = placebo; dGTE = decaffeinated green tea extract; dGTE+ = 
decaffeinated green tea extract with antioxidants; BMI = body mass index. No significant differences 
reported between groups, except age. * denotes significant difference (p ≤ 0.002) to dGTE and 
dGTE+. 
2.2. Study Design and Eligibility 
This study employed a randomised, repeated-measures, double-blinded, placebo-
controlled design over an 8 week period. Following a full study briefing and provision of 
written, informed consent, volunteers took part in an initial pre-screening assessment 
with full familiarisation to the main study testing procedures outlined below. Study eligi-
bility required volunteers to: satisfactorily complete a general health screen questionnaire; 
be over 18 years of age and ‘recreationally active’ (defined as general exercise activity 1–3 
times per week) with a BMI between 25.0 and 29.9 kg·m2 and/or a body fat percentage in 
the overweight category for age/gender based on guidelines set out by the American Col-
lege of Sports Medicine (ACSM) [39]. As a means to further quantify ‘recreationally ac-
tive’, participants were required to have a relative V O2peak between 20 and 45 
mL·kg−1·min−1 during pre-screening testing. Participants with a known history of cardio-
metabolic disorders, blood- and liver-related disorders, and recent viral infections were 
not eligible for study inclusion. Participants were also required to not be consuming other 
nutritional or thermogenic supplements (e.g., GTE, creatine, weight loss products) or 
medication for at least 4 weeks prior to beginning the study intervention. 
2.3. Laboratory Procedures 
All testing procedures were carried out in the Cambridge Centre for Sport and Exer-
cise Sciences, Human Physiology Laboratory, Anglia Ruskin University under controlled 
environmental conditions (M ± SD; temperature: 18.5 ± 1.3 °C; barometric pressure: 1009.4 
± 12.2 mBar; and relative humidity: 44.7 ± 7.8%). In addition to initial pre-screening, par-
ticipants visited the laboratory at baseline (week 0), and at the end of weeks 4 and 8 of the 
intervention period. All testing was undertaken in the morning, with participants being 
tested at the same time of day across the intervention. In the week leading into each la-
boratory visit, participants were required to complete dietary intake and activity diaries 
(see section 2.5). In addition, as a means to standardise each pre-testing period, in the 24 
hours prior, participants were required to rest/no exercise, consume a standardised even-
ing meal (~10 kcal·kg−1, of which 50% carbohydrate, 20% protein, 30% fat), and arrive in a 
euhydrated, fasted state (~10 hours) having refrained from consuming caffeinated prod-
ucts prior to testing.  
Upon arrival, participants rested for ~10 min in a supine position prior to duplicate 
assessment of resting heart rate and blood pressure (Omron 705CP, Kyoto, Japan). Fol-
lowing this, a venous whole blood sample was collected from participants by a qualified 
phlebotomist into triplicate 4 mL serum clot activator Vacuette™ tubes (Greiner Bio-One 
GmbH, Kremsmunster, Austria). Samples were centrifuged for 10 min at 2000 rcf accord-
ing to manufacturer recommendations, with aliquotted serum pipetted into sterile, 
nonpyrogenic, polypropylene cryovials (Fisherbrand, Fisher Scientific, Loughborough, 
UK) and frozen at −80 °C for later assessment of blood analytes (see section 2.6). 
2.3.1. Anthropometric Measures 
Participants then underwent body composition assessment, with height measured 
using a stadiometer (Seca CE123, Hamburg, Germany). Body mass and body fat percent-
age were assessed through the use of bioelectrical impedance analysis scales (Tanita SC-
330ST, Amsterdam, The Netherlands). Body fat percentage was additionally confirmed 
using an 8-site skinfold calliper assessment (following guidelines outlined by the Interna-
tional Society for the Advancement of Kinanthropometry (ISAK)). Specific girth measures 
were undertaken for abdomen, thigh and calf locations, as well as waist to hip ratio (WHR) 
conforming to ISAK/ACSM guidelines. Sagittal abdominal diameter (SAD) was also 
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measured using a Holtain-Kahn abdominal caliper (model 609, Holtain Ltd., Crosswell, 
Pembrokeshire, UK), with visceral fat area (VFA) estimated from validated equations [40]. 
Anthropometric measures were undertaken in triplicate by the same researcher across the 
study period, with average readings for each measure used for analyses. 
2.3.2. Incremental Exercise Fat Oxidation Assessment 
Participants were fitted with a Polar FS2 telemetric heart rate (HR) monitor (Polar 
Electro Ltd., Kempele, Finland) and a suitable face-mask for expired air assessment (Hans 
Rudolph 7450, Cranlea Human Performance Ltd., Bournville, Birmingham, UK) prior to 
an initial resting period. Resting expired air was then measured using a Metalyser 3B au-
tomated gas-analyser (Cortex Biophysik, Leipzig, Germany), after which participants un-
derwent a maximal fat oxidation (‘FATMAX’) test using a Lode Excalibur sport cycle-er-
gometer (Lode B.V., Groningen, The Netherlands). The FATMAX protocol was based on 
original research [41], but modified in line with recent studies involving similar cohorts 
to the present study [42] and pilot work assessment.  
Briefly, participants completed a graded exercise test to volitional exhaustion, start-
ing at 30 W (acting as a warm-up stage) with 20 W increments every 3 min. Cadence was 
maintained between 75 and 85 rpm throughout. Breath-to-breath expired air analysis was 
undertaken throughout the test, along with telemetric HR and self-assessed rating of per-
ceived exertion (RPE)[43] in the last minute of each stage. Maximal individual effort was 
determined when two of the following criteria were met: i) a change in oxygen consump-
tion (VO2) of <2 mL·kg−1·min−1 with increasing workload; ii) attainment of 95% of age-pre-
dicted HRmax (220-age); iii) a respiratory exchange ratio (RER) > 1.05; and iv) an RPE >9 (0–
10 scale) along with evidence of volitional fatigue symptoms. VO2peak was estimated from 
the highest 30 sec moving average oxygen consumption. 
Fat oxidation rates (FATOX; mg·min−1) were derived from VO2 and carbon dioxide 
(VCO2) expired air assessment (L·min−1) using stoichiometric equations [18,44], with pro-
tein oxidation assumed negligible, as follows: 




Using individual FATOX data for each stage plotted against exercise intensity 
(%VO2peak), a 2nd-order polynomial curve was fitted from which maximal fat oxidation rate 
(MFO; mg·min−1), maximal fat oxidation exercise intensity (FATMAX, defined as %VO2peak 
at which MFO occurred) and minimum fat oxidation exercise intensity (FATMIN, defined 
as the %VO2peak where FATOX was deemed zero) were derived, based on previous research 
[45]. 
2.3.3. Steady State Exercise Assessment 
Following a standardised 30 min rest period (with resting VO2 and HR comparable 
to pre-exercise conditions), participants underwent a fixed-intensity exercise test (60% of 
individual VO2peak), using the same cycle-ergometer, with cadence maintained between 75 
and 85 rpm for 60 min. Perceived exertion and HR were measured at 5 min and each 15 
min thereafter. Breath-to-breath expired air was continuously measured throughout the 
submaximal exercise period, with 60 sec average data recorded upon test completion. Fat 
oxidation rates were derived from the previous stoichiometric equation (1). Carbohydrate 
oxidation rates (CHOOX; mg·min−1) and energy expenditure (EE; kcal·min−1) were derived 
from the following equations [44]: 
CHOOX = (4.210 × VCO2) – (2.962 × VO2), (2)
EE = (0.550 × VCO2) + (4.471 × VO2), (3) 
Additionally, both fat and carbohydrate oxidation stability (expressed as a %) were 
assessed on the basis of the duration maintained within ± 10% of mean FATOX and CHOOX 
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rates, respectively. Contributions of both carbohydrate and fat to EE were calculated on 
the basis of caloric conversion of estimated total CHOOX and FATOX (g·h−1) expressed as a 
percentage of EE (kcal·h−1). 
2.4. Nutritional Interventions 
Following baseline assessment, participants were allocated, in a double-blinded 
manner, to one of three intervention groups using a random number generator (www.ran-
domizer.org). Participants were randomly assigned to an 8 week intervention (2 hydrox-
ypropyl methyl cellulose capsules daily, split dose taken away from food) of either: (i) 
placebo (PL; containing a total of 892 mg·d−1 potato fibre as a bulking agent); (ii) decaffein-
ated green tea extract (dGTE; 580 mg·d−1 dGTE, 70% standardised, delivering 400 mg·d−1 
EGCG, matched weighted with additional bulking agent, negligible caffeine trace 
(≤0.5%)); or (iii) a novel decaffeinated green tea extract formula (dGTE+; 580 mg·d−1 dGTE 
(400 mg·d−1 EGCG, negligible caffeine trace ≤0.5%), with quercetin (50 mg·d−1) and α-lipoic 
acid (LA; 150 mg·d−1), also matched weighted with additional bulking agent).  
All supplementation was supplied and pre-capsulated by Biocare Ltd. (Redditch, Bir-
mingham, UK), and verified through Nutraceuticals Group Europe (Merstham, Surrey, 
UK) with dGTE sourced from Changsha Active Ingredients Group Inc. (Changsha, 
China), based on our previous research [25]. All supplements were provided in standard-
ised opaque sealed pots for hygiene and double-blinding purposes. To monitor supple-
ment adherence, participants completed a daily compliance record throughout the inter-
vention. As a further measure, participants were initially provided a 4 week supplement 
supply and returned pots at the first follow-up session, with excess capsules counted. Par-
ticipants were then provided with a second 4 week supply, with pots returned and 
checked at the final testing session, and overall adherence levels cross-referenced against 
compliance records. A threshold target of 90% adherence was used for protocol compli-
ance. 
2.5. Dietary Intake and Exercise Monitoring 
Following the pre-screening session, participants included in the main intervention 
completed a 7 day food diary using a smart phone application (www.MyFitnessPal.com), 
validated in previous research [46,47]. This served partly as a familiarisation process, and 
also to gain awareness of typical individual dietary intakes. Throughout this study, par-
ticipants were requested to maintain typical dietary patterns for consistency. Further-
more, in the 7 day period leading into each laboratory session, participants completed a 
habitual record of dietary intake to assess for consistency. Individual guidance was pro-
vided in diary collation, with emphasis on meal content, portion size and weight, and 
fluid intake. Diaries were assessed using Nutritics Professional Dietary Analysis software 
(Nutritics Ltd., Co. Dublin, Ireland) by the same researcher. In addition, individual food 
items were cross referenced against the U.S. Department of Agriculture (USDA) database 
on the flavonoid content of selected foods, and the Phenol-Explorer database (www.phe-
nol-explorer.eu) as a means to estimate dietary quercetin intake. 
In conjunction with this, participants were also provided with a standard activity log 
and HR monitor, and requested to track all exercise activity prior to the start of the inter-
vention (acting as habitual reference), and each week across the 8 week study period. Par-
ticipants recorded exercise activity, mean session HR, duration and overall session rating 
of perceived exertion (sRPE) from which training load, monotony and strain were deter-
mined as previously described [48,49]. To standardise weekly physical activity, and 
aligned with participants’ habitual exercise patterns, following the baseline laboratory 
session, participants were provided with general exercise guidance to be maintained 
throughout this study. This involved targeting ~150 min of moderate aerobic exercise (~3–
5 sessions·wk−1), at ~60–65%VO2peak (~75–80%HRmax) in accordance with guidelines set out 
by the American College of Sports Medicine [39,50]. 
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2.6. Biochemical Assays 
All blood samples were analysed independently in conjunction with the NIHR Cam-
bridge Biomedical Research Centre, Core Biochemical Analysis Laboratory (CBAL), Ad-
denbrookes Hospital, Cambridge. Serum samples were assessed at week 0, 4 and 8 using 
a Siemens Dimension EXL analyser (Siemens Healthcare Ltd., Camberley, Surrey, UK) for 
the following analytes (between-batch imprecision (BBI) included): glucose (BBI: 3.6% at 
3.5 mmol·L−1); triglycerides (Tg; BBI: 5.5% at 0.9 mmol·L−1, 3.4% at 2.4 mmol·L−1); total cho-
lesterol (Tc; BBI: 4.9% at 2.5 mmol·L−1, 2.0% at 6.2 mmol·L−1); and HDL-c (BBI: 4.6% at 0.9 
mmol·L−1, 3.6% at 2.3 mmol·L−1), with LDL-c (BBI: 3.9% at 1.4 mmol·L−1, 5.0% at 3.2 
mmol·L−1) derived from the Friedewald equation [51] as follows: 
LDL-c = Tc –HDL-c – (Tg/2.2), (4) 
Additionally, serum insulin was assessed using a sandwich chemiluminescence im-
munoassay via a DiaSorin Liaison XL analyser (DiaSorin, Saluggia (VC), Italy), with BBI 
noted as 11.0% at 34.0 pmol·L−1 and 7.0% at 135.0 pmol·L−1. An updated Homeostasis 
Model Assessment (HOMA) was employed to estimate steady state beta cell function 
(%B), insulin sensitivity (%S) and insulin resistance (IR) using a HOMA2 calculator 
(v2.2.3., Diabetes Trials Unit, University of Oxford, UK) based on previous research [52]. 
Serum glycerol was quantified using a coupled enzyme assay involving glycerol kinase 
and glycerol phosphate oxidase (Sigma-Aldrich, Merck Life Science UK Ltd., Gillingham, 
Dorset, UK; no BBI quoted). Based on the enzymatic conversion of free fatty acids (FFA) 
to acyl CoA by acyl-Co A synthetase, FFA were determined using a Roche half-micro test 
assay kit (Sigma-Aldrich, Merck Life Science UK Ltd., Gillingham, Dorset, UK; BBI: 12.5% 
at 122 µmol·L−1, 4.5% at 466 µmol·L−1). Serum leptin and adiponectin were assessed using 
an AutoDELFIA analyser (Perkin Elmer LAS (UK) Ltd., Beaconsfield, Buckinghamshire, 
UK), employing in-house two-site microtiter plate-based DELFIA assay (BBI for leptin: 
7.1% at 2.7 ng·ml−1, 3.9% at 14.9 µg·ml−1 and 5.7% at 54.9 µg·ml−1; BBI for adiponectin: 5.4% 
at 3.6 µg·ml−1, 5.2% at 9.2 µg·ml−1 and 5.8% at 15.5 µg·ml−1), with antibodies and standards 
supplied by R&D systems (R&D Systems Europe, BioTechne, Abingdon, UK).  
An important feature of the current study, and with recent concerns around potential 
for high-dose catechin-related hepatic toxicity, a liver enzyme panel was also carried out 
using a Siemens Dimension EXL analyser (Siemens Healthcare Ltd., Camberley, Surrey, 
UK) for the following analytes: alkaline phosphatase (ALP; BBI: 16.3% at 40 U·L−1, 6.4% at 
282 U·L−1); alanine aminotransferase (ALT; BBI: 8.1% at 22 U·L−1, 3.6% at 180 U·L−1); aspar-
tate aminotransferase (AST; BBI: 5.0% at 38 U·L−1, 2.5% at 253 U·L−1); and bilirubin (BBI: 
2.7% at 14 µmol·L−1 , 1.0% at 74 µmol·L−1). As a means to detect any acute elevations in 
liver enzymes, participants also had an additional blood sample collected at week 2 of the 
intervention as a precautionary measure.  
2.7. Statistical Analyses 
Statistical analyses were performed using SPSS (IBM, Version 26.0). Normality of 
data was verified by the Shapiro–Wilk test. Outliers were identified by inspection of box 
plots > 1.5 interquartile range in SPSS. Baseline measures were assessed using a between-
groups analysis of variance (ANOVA), or where applicable (e.g., dietary analyses) an in-
dependent samples t-test was employed. A mixed-design repeated-measures ANOVA 
(group, time) were performed for main analyses, with Bonferroni post-hoc comparisons 
where applicable. Where sphericity was violated a Greenhouse–Geisser correction was 
applied. An alpha level of ≤0.05 was employed for statistical significance, with effect size 
(partial eta squared; ηp2) also reported (small = 0.02, medium= 0.13, large = 0.26). Data are 
reported as the mean ± SE. 
  




3.1. Dietary Intake, Supplement Adherance and Exercise Monitoring 
Dietary analysis comparisons across the intervention are shown in Table 2. No sig-
nificant differences were reported between or within groups across the 8 week interven-
tion period for energy, carbohydrate, fat or protein intake (p > 0.05). In addition, no differ-
ences were reported between mean energy intake compared with expected maintenance 
caloric intake (p > 0.05) overall or within groups at week 4 or 8, demonstrating dietary 
consistency. 
Across the 8 week intervention, average daily energy intake for dGTE+ was 1918 ± 66 
kcal·d−1 (or 25.7 ± 1.2 kcal·kg−1·day−1) compared with 1882 ± 96 kcal·d−1 (or 25.6 ± 1.2 
kcal·kg−1·day−1) for dGTE, and 1975 ± 96 kcal·d−1 (or 24.3 ± 1.5 kcal·kg−1·day−1) for PL. Mac-
ronutrient intake was also comparable, with an average fat intake of 1.0 ± 0.1 g·kg−1·day−1 
for dGTE+ compared 0.9 ± 0.1 g·kg−1·day−1 for dGTE and 0.9 ± 0.1 g·kg−1·day−1 for PL. Like-
wise, average carbohydrate intake was 2.7 ± 0.2 g·kg−1·day−1 for dGTE+ compared with 3.0 
± 0.2 g·kg−1·day−1 for dGTE and 2.7 ± 0.2 g·kg−1·day−1 for PL. Similarly, average protein 
intake was comparable between groups at 1.1 ± 0.1 g·kg−1·day−1 for dGTE+, 1.2 ± 0.1 
g·kg−1·day−1 for dGTE, and 0.9 ± 0.0 g·kg−1·day−1 for PL.  
Estimation of dietary quercetin highlighted a mean overall intake of 20.6 ± 8.5 mg·d-
1, with no differences reported between groups (20.1 ± 7.3 mg·d-1 for PL; 20.0 ± 8.8 mg·d-1 
for dGTE; and 21.8 ± 10.4 mg·d-1 for dGTE+, p > 0.05). Mean adherence to the supplement 
intervention was 95.4 ± 1.0%. Within groups, adherence rates were 93.0 ± 1.1%, 96.3 ± 0.8% 
and 96.9 ± 1.3% for PL, dGTE and dGTE+, respectively, with a significant difference re-
ported between PL and dGTE+ (p = 0.04) only. 
Table 2. Mean relative energy and macronutrient intake comparisons between groups. 
Variable PL dGTE dGTE+ 
Energy intake (kcal·kg−1·day−1) 
Baseline 23.7 ± 1.2 25.8 ± 1.4 25.4 ± 1.3 
Week 4 24.8 ± 1.8 25.4 ± 1.6 26.1 ± 1.7 
Week 8 24.4 ± 1.5 25.5 ± 1.3 25.6 ± 1.6 
Fat (g·kg−1·day−1) 
Baseline 0.9 ± 0.1 0.9 ± 0.1 1.0 ± 0.1 
Week 4 1.0 ± 0.1 0.8 ± 0.1 1.0 ± 0.1 
Week 8 0.9 ± 0.1 0.9 ± 0.1 1.0 ± 0.1 
Carbohydrate (g·kg−1·day−1) 
Baseline 2.8 ± 0.2 3.0 ± 0.2 2.7 ± 0.2 
Week 4 2.7 ± 0.3 3.1 ± 0.2 2.8 ± 0.3 
Week 8 2.7 ± 0.2 3.0 ± 0.2 2.7 ± 0.2 
Protein (g·kg−1·day−1) 
Baseline 0.9 ± 0.0 1.2 ± 0.1 1.1 ± 0.1 
Week 4 0.9 ± 0.1 1.2 ± 0.2 1.1 ± 0.1 
Week 8 1.0 ± 0.1 1.1 ± 0.1 1.1 ± 0.1 
Data represent average daily intake. PL = placebo; dGTE = decaffeinated green tea extract; dGTE+ = 
decaffeinated green tea extract with antioxidants. No significant differences reported between or 
within groups (p > 0.05). 
Exercise monitoring training load comparisons are shown in Table 3. No significant 
differences were reported between groups across the intervention for training load, mo 
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notony or strain (p > 0.05) demonstrating relative consistency. Mean weekly duration was 
reported at 189.7 ± 22.4 min, 204.0 ± 20.9 min and 196.4 ± 29.1 min for PL, dGTE and 
dGTE+, respectively (p > 0.05), meeting expected recommendations. No significant differ-
ences were observed for mean HR compared to training recommendations (75–80%HRmax) 
for PL (82 ± 2%HRmax), dGTE (79 ± 2%HRmax) and dGTE+ (79 ± 1%HRmax), respectively (p > 
0.05). 
Table 3. Estimated mean training load, monotony and strain between intervention groups prior to 
and across the experimental period. 
Variable PL dGTE dGTE+ 
Weekly training load (AU) 
Baseline 869 ± 129 1134 ± 136 848 ± 144 
Week 4 996 ± 139 893 ± 127 918 ± 96 
Week 8 888 ± 166 850 ± 99 795 ± 141 
Training monotony (AU) 
Baseline 0.85 ± 0.08 0.92 ± 0.12 0.90 ± 0.07 
Week 4 0.82 ± 0.05 0.89 ± 0.07 1.02 ± 0.09 
Week 8 0.78 ± 0.02 0.92 ± 0.08 0.98 ± 0.16 
Training strain (AU) 
Baseline 764 ± 139 1090 ± 205 819 ± 223 
Week 4 787 ± 88 824 ± 143 1070 ± 188 
Week 8 666 ± 116 804 ± 137 969 ± 350 
Data represent arbitrary units (AU). PL = placebo; dGTE = decaffeinated green tea extract; dGTE+ = 
decaffeinated green tea extract with antioxidants. No significant differences reported between or 
within groups (p > 0.05). 
3.2. Fat Oxidation Data 
Mean fat oxidation measures are shown in Table 4, with normalised fold change 
shown in Figure 1. No significant differences were reported at baseline for all variables (p 
> 0.05). A significant interaction effect was found for maximal fat oxidation (MFO; F = 3.41, 
p = 0.016, ηp2 = 0.22), with post-hoc analysis highlighting a 45.4% increase in MFO for 
dGTE+ at week 8 (p = 0.009) compared to baseline only. This was supported with a noted 
trend at week 4 for dGTE+ (p = 0.063) also compared to baseline. Similarly, dGTE+ resulted 
in 49.4% increase in relative MFO (interaction effect; F = 3.67, p = 0.011, ηp2 = 0.23) by week 
8 compared to baseline (p = 0.024), with a trend noted compared to week 4 (p = 0.059). 
dGTE had a positive, but non-significant impact on MFO (+12.7%) and MFO·FFM−1 
(+13.9%), whereas PL resulted in a non-significant reduction in MFO (−11.8%) and 
MFO·FFM−1 (−21.4%; p > 0.05).  
In terms of normalised fold change (Figure 1), a significant effect for MFO was re-
ported overall by week 8 (F = 3.81, p = 0.037, ηp2 = 0.24), but not by week 4 (p = 0.113). 
Normalised MFO was significantly greater with dGTE+ only (+0.65 ± 0.25 fold change) 
compared with PL (−0.11 ± 0.09 fold change; p = 0.034) across the intervention. Similarly, 
normalised relative MFO was significantly different between groups by week 8 (F = 4.16, 
p = 0.028, ηp2 = 0.26) but not by week 4 (p = 0.073), again with a highlighted increase for 
dGTE+ (+0.76 ± 0.24 fold change) compared with PL (−0.16 ± 0.11 fold change; p = 0.026).   
 No significant effects were found for FATMAX or HR at FATMAX within or between 
groups (p > 0.05). However, a positive interaction effect was observed for FATMIN (F = 6.02, 
p = 0.001, ηp2 = 0.33), with dGTE+ resulting in a 22.5% increase in FATMIN by week 8 com-
pared with week 4 (p = 0.003) and a trend noted compared to baseline (p = 0.056). When 
expressed as normalised fold change, a significant effect was found for FATMIN by week 8 
(F = 4.77, p = 0.018, ηp2 = 0.28), with dGTE+ demonstrating a +0.18 ± 0.08 fold change com 
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pared with PL (-0.08 ± 0.05; p = 0.023). Throughout the intervention, as expected, VO2peak 
was maintained for PL: 2.5 ± 0.2 L·min−1, 2.4 ± 0.1 L·min−1 and 2.4 ± 0.1 L·min−1; dGTE: 2.4 
± 0.2 L·min−1, 2.5 ± 0.2 L·min−1, and 2.4 ± 0.2 L·min−1; and dGTE+: 2.1 ± 0.2 L·min−1, 2.3 ± 0.2 
L·min−1, and 2.1 ± 0.2 L·min−1, with no differences reported within or between groups at 
week 0, 4 and 8, respectively (p > 0.05).
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Table 4. Mean fat oxidation measures at baseline (week 0), week 4 and 8 between intervention groups. 
 PL  dGTE  dGTE+ 
Variable Baseline Week 4 Week 8  Baseline Week 4    Week 8    Baseline  Week 4       Week 8 
MFO (mg·min-1) 228.1 ± 23.4 219.5 ± 34.1 201.1 ± 25.2  199.0 ± 30.8 223.2 ± 32.3 224.4 ± 27.8  154.4 ± 20.6 176.6 ± 19.3 224.6 ± 23.2 * 
MFO·FFM-1 (mg·min-1) 4.7 ± 0.7 4.1 ± 0.6 3.7 ± 0.5  4.0 ± 0.6 4.4 ± 0.6 4.5 ± 0.5  3.2 ± 0.4 3.7 ± 0.4 4.7 ± 0.5 * 
FATMAX (%VO2peak) 35.2 ± 2.0 38.6 ± 2.2 38.0 ± 1.9  36.5 ± 6.0 34.1 ± 1.8 36.5 ± 2.9  39.5 ± 2.6 34.4 ± 1.3 42.7 ± 2.3 
FATMAX HR (%HRmax) 57.6 ± 1.9 58.5 ± 2.1 57.7 ± 1.7  56.3 ± 1.5 57.9 ± 1.6 56.8 ± 1.7  57.1 ± 1.7 57.5 ± 2.1 58.1 ± 1.6 
FATMIN (%VO2peak) 61.7 ± 4.3 64.7 ± 4.2 56.1 ± 4.0  60.1 ± 4.1 54.9 ± 3.4    57.2 ± 3.6     58.3 ± 2.6     55.1 ± 1.9     67.6 ± 3.6 # 
PL = placebo; dGTE = decaffeinated green tea extract; dGTE+ = decaffeinated green tea extract with antioxidants. MFO = maximal fat oxidation rate; MFO·FFM−1 = relative maximal fat 
oxidation rate (per kg FFM); FATMAX= exercise intensity at which MFO occurs; FATMAX HR = heart rate at MFO expressed relative to maximum HR; FATMIN = exercise intensity where 
FATOX deemed zero. * significantly different from baseline within group (p ≤ 0.024); # significantly different to week 4 within group (p = 0.003.
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Figure 1. Mean normalised fold change for FATMAX test parameters between groups by week 4 (Δ 0−4 
weeks) and week 8 (Δ 0−8 weeks) of the intervention; showing (A) maximal fat oxidation rate (MFO), 
(B) relative maximal fat oxidation rate per kg FFM (MFO·FFM−1), (C) exercise intensity at which MFO 
occurs (FATMAX), and (D) exercise intensity where fat oxidation deemed zero (FATMIN). PL = placebo; 
dGTE = decaffeinated green tea extract; dGTE+ = decaffeinated green tea extract with antioxidants. * 
significantly different from PL (p ≤ 0.034). 
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3.3. Steady State Exercise Data 
Mean steady state exercise measures are shown in Table 5, with normalised fat oxi-
dation data shown in Figure 2. Mean exercise intensity during laboratory testing was com-
parable across the intervention (baseline: 60.2 ± 1.4%𝑉O2peak, 𝑉O2: 1.4 ± 0.1 L·min−1; week 
4: 59.8 ± 1.6%𝑉O2peak, 𝑉O2: 1.4 ± 0.1 L·min−1; week 8: 58.7 ± 1.5%𝑉O2peak, 𝑉O2: 1.4 ± 0.1 
L·min−1; p > 0.05), with no differences reported within or between groups, or compared to 
set exercise intensity (p > 0.05). No significant differences were reported at baseline for all 
variables (p > 0.05). A significant interaction effect was found for mean RER (F = 4.66, p = 
0.003, ηp2 = 0.28), with post-hoc analyses revealing a reduction in RER by week 8 for dGTE+ 
compared with week 4 (p = 0.004). When normalised data were considered, a significant 
overall between-group effect was found for RER (F = 4.22, p = 0.027, ηp2 = 0.26), highlighting 
a difference between dGTE and dGTE+ by week 8 (p = 0.034). 
Whilst a significant interaction effect was also found for mean FATOX during steady 
state exercise (F = 3.15, p = 0.022, ηp2 = 0.21), no significant post-hoc analyses were found, 
despite a +28.4% increase in steady state FATOX by week 8 with dGTE+ (p > 0.05). However, 
a significant interaction was found with relative FATOX (F=3.98, p=0.007, ηp2 = 0.25), with a 
+54.2% increase in FATOX·FFM−1 by week 8 compared to week 4 for dGTE+ only (p = 0.036). 
Normalised data also highlighted a significant between-group effect for FATOX by week 8 
(F = 4.050, p = 0.031, ηp2 = 0.252) with a +0.84 ± 0.48 fold change for dGTE+ compared with 
both PL (−0.22 ± 0.14) and dGTE (−0.22 ± 0.15). However, post-hoc analyses only revealed 
a trend between PL and dGTE (p = 0.064) and dGTE and dGTE+ (p = 0.063). A similar 
pattern was found for normalised FATOX·FFM−1 (F = 3.93, p = 0.033, ηp2 = 0.25), with no 
significant post-hoc analyses (PL compared with dGTE, p = 0.071; dGTE compared with 
dGTE+, p = 0.068). 
No significant effects were found for mean carbohydrate oxidation stability, despite 
a noted -11.9% reduction by week 8 for dGTE+ (p > 0.05). Similarly, mean fat oxidation 
stability did not significantly improve with either dGTE formula, despite an observed 
trend (interaction effect: F = 2.36, p = 0.066, ηp2 = 0.16) by week 8 for dGTE+. No significant 
differences were observed for normalised data for carbohydrate or fat oxidation stability 
at week 4 or 8 (p > 0.05). No significant differences were reported for EE within or between 
groups (p > 0.05). However, a significant interaction effect was found for both the contri-
bution of carbohydrate (F = 4.37, p = 0.004, ηp2 = 0.27) and the contribution of fat (F = 4.29, 
p = 0.005, ηp2 = 0.26) to EE, highlighting a -17.8% reduction in carbohydrate contribution (p 
= 0.008) and a +64.8% increase in fat contribution (p = 0.006) to EE for dGTE at week 8 
compared to week 4, respectively. When normalised data were considered, a significant 
between-group effect was observed for both carbohydrate (F = 3.66, p = 0.041, ηp2 = 0.23) 
and fat (F = 3.73, p = 0.039, ηp2 = 0.237) contribution to EE by week 8. However, post-hoc 
analyses only indicated a difference between dGTE and dGTE+ for carbohydrate contri-
bution to EE (p = 0.043), but not fat contribution (p = 0.083).
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Table 5. Mean steady state exercise measures at baseline (week 0), week 4 and 8 between intervention groups. 
 PL  dGTE  dGTE+ 
Variable Baseline Week 4 Week 8  Baseline Week 4 Week 8  Baseline Week 4 Week 8 
RER 0.91 ± 0.01 0.90 ± 0.02 0.92 ± 0.02  0.90 ± 0.02 0.92 ± 0.02 0.93  ± 0.01  0.92 ± 0.01 0.94 ± 0.01 0.89 ± 0.01 * 
FATOX (mg·min-1) 224.4 ± 27.7 237.3 ± 48.9 181.6 ± 36.8  222.3 ± 41.4 185.7 ± 41.1 161.3 ± 31.1  169.1 ± 37.6 152.6 ± 45.8 217.2 ± 31.7 
FATOX·FFM-1 (mg·min-1) 4.1 ± 0.5 4.4 ± 0.9 3.3 ± 0.6  4.5 ± 0.8 3.6 ± 0.7 3.2 ± 0.6  3.4 ± 0.7 2.9 ± 0.7 4.5 ± 0.7* 
CHOOXST (%) 62.6 ± 5.5 61.2 ± 5.2 68.2 ± 4.1  64.4 ± 3.9 67.6 ± 4.8 63.5 ± 5.3  72.0 ± 2.8 71.7 ± 2.1 63.1 ± 4.2 
FATOXST (%) 31.5 ± 5.0 35.4 ± 7.5 28.3 ± 6.0  34.4 ± 7.4 32.2 ± 5.7 26.5 ± 5.5  27.8 ± 5.5 22.5 ± 4.6 36.8 ± 5.3 
Total EE (kcal.hr-1) 446.6 ± 27.6 420.4 ± 25.8 435.8 ± 27.1  421.0 ± 30.4 407.5 ± 31.8 404.4 ± 29.0  377.9 ± 28.9 383.3 ± 39.4 374.4 ± 30.3 
CHOcont. EE (%) 69.9 ± 4.0 67.1 ± 6.9 75.2 ± 5.2  69.1 ± 6.0 74.3 ± 5.8 77.4 ± 4.6  75.0 ± 4.6 79.7 ± 4.5 65.5 ± 4.6 * 
FATcont. EE (%) 30.3 ± 4.1 33.4 ± 6.8 25.3 ± 5.1  31.4 ± 5.8 26.5 ± 5.4 23.3 ± 4.4  25.0 ± 4.6 21.0 ± 4.1   34.6 ± 4.7 * 
PL = placebo; dGTE = decaffeinated green tea extract; dGTE+ = decaffeinated green tea extract with antioxidants. RER = respiratory exchange ratio; FATOX = fat oxidation rate; FA-
TOX·FFM−1 = relative fat oxidation rate (per kg FFM); CHOOXST= carbohydrate oxidation stability (expressed as %); FATOXST = fat oxidation stability (expressed as %); EE = energy 
expenditure; CHOcont.EE = contribution of carbohydrate to total EE; FATcont.EE = contribution of fat to total EE. * significantly different to week 4 within condition (p ≤ 0.036).





























































































































Figure 2. Mean normalised fold change for fat oxidation parameters during steady state exercise be-
tween groups by week 4 (Δ 0−4 weeks) and week 8 (Δ 0−8 weeks) of the intervention; showing (A) 
respiratory exchange ratio (RER), (B) fat oxidation rate (FATOX), (C) fat oxidation stability (FATOXST), 
and (D) contribution of fat to total energy expenditure (FATcont.EE). PL = placebo; dGTE = decaffein-
ated green tea extract; dGTE+ = decaffeinated green tea extract with antioxidants. * significantly dif-
ferent to dGTE only (p = 0.034). 
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3.4. Body Composition, HR and Blood Pressure 
Mean body composition, resting HR and blood pressure measures are shown in Ta-
ble 6. No significant differences were reported at baseline for all variables (p > 0.05). No 
significant differences were observed for body mass, BMI, body fat, fat-free mass, fat mass, 
WHR, SAD, VFA or blood pressure within or between groups (p > 0.05). A main effect was 
reported for waist circumference (F = 4.65, p = 0.014, ηp2 = 0.16), with a -0.8 ± 0.2 cm relative 
decrease at week 4 compared to baseline for PL only (p = 0.019). A main effect was also 
reported for abdominal circumference (F = 6.19, p = 0.004, ηp2 = 0.21), with a -1.6 ± 0.4 cm 
relative decrease by week 4 for dGTE compared to baseline (p = 0.004). Resting HR was 
significantly reduced by week 4 for dGTE+ compared with dGTE only (main interaction; 
F = 2.61, p = 0.047, ηp2 = 0.18).
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Table 6. Body composition, resting heart rate and blood pressure measures at baseline (week 0), week 4 and 8 between intervention groups. 
 PL  dGTE  dGTE+ 
Variable Baseline Week 4 Week 8  Baseline Week 4 Week 8  Baseline Week 4 Week 8 
Body mass (kg) 82.7 ± 4.3 82.5 ± 4.3 82.6 ± 4.2  74.3 ± 2.5 73.8 ± 2.3 73.9  ± 2.4  75.6 ± 3.1 75.3 ± 3.2 75.1 ± 3.1 
BMI (kg·m2) 28.2 ± 1.4 28.1 ± 1.4 28.2 ± 1.3  26.8 ± 0.8 26.7 ± 0.9 26.7 ± 0.9  27.1 ± 0.8 27.1 ± 0.8 27.0 ± 0.9 
Body fat (%) 32.0 ± 2.6 31.7 ± 2.5 32.2 ± 2.7  33.2 ± 2.2 32.7 ± 2.3 32.9 ± 2.2  36.3 ± 2.1 36.1 ± 2.1 35.8 ± 2.2 
FFM (kg) 56.1 ± 3.4 55.9 ± 3.2 55.5 ± 3.1  49.6 ± 2.5 49.7 ± 2.5 49.5 ± 2.4  48.0 ± 2.5 48.0 ± 2.5 48.2 ± 2.4 
FM (kg) 26.6 ± 2.8 26.3 ± 2.7 26.7 ± 2.8  24.6 ± 1.8 24.1 ± 1.9 24.3 ± 1.8  27.3 ± 2.1 27.3 ± 2.3 27.0 ± 2.4 
W:H 0.84 ± 0.03 0.83 ± 0.02 0.83 ± 0.03  0.82 ± 0.02 0.82 ± 0.02 0.83 ± 0.02  0.80 ± 0.01 0.80 ± 0.01 0.80 ± 0.01 
Waist C (cm) 89.5 ± 3.2 88.7 ± 3.1 * 89.0 ± 3.0  85.7 ± 2.4 85.3 ± 2.5 85.8 ± 2.6  85.2 ± 2.0 84.9 ± 1.9 84.9 ± 2.0 
Ab. C (cm) 102.0 ± 2.3 101.8 ± 2.6 101.9 ± 2.6  100.8 ± 2.8 99.2 ± 2.7 * 99.7 ± 2.8  100.9 ± 2.9 100.4 ± 2.9 100.1 ± 2.9 
SAD (cm) 23.3 ± 0.9 23.1 ± 0.9 23.0 ± 0.9  21.6 ± 0.5 21.1 ± 0.7 21.3 ± 0.7  21.9 ± 0.7 21.6 ± 0.7 21.3 ± 0.8 
VFA (cm2) 1740.1 ± 140.8 1739.3 ± 151.8 1714.8 ± 135.7  1576.0 ± 116.1 1554.7 ± 134.4 1550.1 ± 151.1  1778.4 ± 143.8 1748.3 ± 136.6 1699.6 ± 161.7 
HR (b·min-1) 68 ± 3 65 ± 2 69 ± 4  62 ± 3 68 ± 4 65 ± 2  63 ± 2 58 ± 1 # 60 ± 2 
SBP (mmHg) 130 ± 9 128 ± 9 128 ± 8  117 ± 3 120 ± 4 115 ± 4  114 ± 6 113 ± 4 111 ± 4 
DBP (mmHg) 84 ± 5 84 ± 6 84 ± 5  78 ± 2 78 ± 1 78 ± 2  77 ± 3 77 ± 3 75 ± 2 
PL = placebo; dGTE = decaffeinated green tea extract; dGTE+ = decaffeinated green tea extract with antioxidants. BMI = body mass index; FFM = fat free mass; FM = fat mass; WHR = 
waist to hip ratio; waist C = waist circumference; Ab. C = abdominal circumference; SAD = sagittal abdominal diameter; VFA = estimated visceral fat area; HR = resting heart rate; SBP 
= systolic blood pressure; DBP = diastolic blood pressure. * significantly different to baseline within group only (p ≤ 0.019). # significantly different to dGTE at timepoint (p = 0.05).
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3.5. Blood Analytes 
Mean serum cardio-metabolic markers, including normalised fold change, are shown 
in Tables 7 and 8. No significant differences were reported at baseline for all variables (p 
> 0.05), except adiponectin. Mean adiponectin levels for dGTE+ were significantly greater 
compared to PL at baseline (p = 0.036), week 4 (p = 0.021) and week 8 (p = 0.049). No other 
main effects were found for all variables, except for LDL-c, where a main interaction effect 
was observed (F = 2.75, p = 0.039, ηp2 = 0.19). However, post-hoc analyses did not reveal 
any significant differences for LDL-c within or between groups despite a relative -0.38 ± 
0.22 mmol·L−1 reduction for dGTE+, and a relative +0.30 ± 0.12 mmol·L−1 increase for dGTE 
over the intervention. When data were normalised, a significant interaction effect was 
found for LDL-c over the intervention (F = 3.95, p = 0.033, ηp2 = 0.25) highlighting the dif-
ference between dGTE and dGTE+ only (p= 0.038). 
Mean serum liver function markers, including normalised fold change, are shown in 
Tables 9 and 10. All mean data were considered within normal reference ranges for all 
variables. No significant effects were found for ALT, AST or bilirubin, despite relative 
reductions of -16.22 ±11.52 U·L−1, -8.22 ± 7.43 U·L−1 and -0.89 ± 1.78 µmol·L−1, respectively, 
by week 8 for PL (p > 0.05). However, ALP significantly reduced by -6.67 ± 3.03 U·L−1 over 
time (F = 6.63, p = 0.003, ηp2 = 0.22) for PL only (p ≤ 0.025 for both baseline and week 4 
compared with week 8). When data were normalised, a significant between-group effect 
was reported overall for ALT only (F = 4.88, p = 0.017, ηp2 = 0.29), with the highlighted 
difference between PL and dGTE+ (p = 0.015) likely explained by the relative decrease for 
ALT in PL over time. All liver enzymes, and bilirubin, were unaffected by both dGTE and 
dGTE+ supplementation.
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Table 7. Mean serum cardio-metabolic markers at baseline (week 0), week 4 and 8 between intervention groups. 
 PL  dGTE  dGTE+ 
Variable Baseline Week 4 Week 8  Baseline Week 4 Week 8  Baseline Week 4 Week 8 
Glucose (mmol·L-1) 5.36 ± 0.10 5.37 ± 0.14 5.41 ± 0.13  5.78 ± 0.17 5.53 ± 0.21 5.57  ± 0.22  5.32 ± 0.16 5.29 ± 0.13 5.23 ± 0.15 
Insulin (pmol·L-1) 61.67 ± 12.34 66.33 ± 13.66 71.33 ± 15.38  48.44 ± 6.04 48.22 ± 5.91 43.78 ± 4.85  39.67 ± 5.47 49.00 ± 7.00 43.22 ± 7.01 
%B 88.06 ± 9.87 92.13 ± 9.98 94.94 ± 9.80  66.02 ± 5.07 71.70 ± 4.05 68.57 ± 6.08  67.80 ± 5.83 79.64 ± 7.27 73.09 ± 4.82 
%S 114.63 ± 23.30 100.87 ± 15.19 91.07 ± 11.66  121.32 ± 15.36 121.12 ± 14.40 132.39 ± 19.49  155.48 ± 21.10 131.66 ± 25.71 150.53 ± 26.62 
HOMA-IR 1.19 ± 0.23 1.26 ± 0.26 1.35 ± 0.29  0.94 ± 0.12 0.93 ± 0.12 0.85 ± 0.09  0.76 ± 0.11 0.95 ± 0.12 0.84 ± 0.13 
Leptin (ng·mL-1) 15.88 ± 3.83 16.69 ± 4.00 18.78 ± 3.61  17.59 ± 4.28 18.58 ± 5.39 17.46 ± 3.75  24.66 ± 5.50 24.19 ± 6.25 25.21 ± 5.89 
Adiponectin (µg·mL-1) 5.94 ± 1.50 5.79 ± 1.47 5.82 ± 1.35  9.06 ± 1.16 8.90 ± 1.30 9.39 ± 1.45  11.17 ± 1.40* 11.54 ± 1.37* 11.08 ± 1.50* 
Glycerol (µmol·L-1) 25.44 ± 3.09 27.56 ± 3.50 27.00 ± 2.40  28.00 ± 2.70 36.44 ± 4.61 29.89 ± 3.89  31.56 ± 6.31 29.78 ± 3.42 31.11 ± 3.58 
FFA (µmol·L-1) 310.56 ±  58.61 298.44 ± 55.71 282.56 ± 39.07  347.89 ± 51.81 436.44 ± 72.00 359.56 ± 37.09  304.22 ± 69.82 296.56 ± 36.29 287.78 ± 36.61 
CholTOT (mmol·L-1) 5.06 ± 0.27 5.04 ± 0.21 5.17 ± 0.20  5.16 ± 0.25 5.34 ± 0.28 5.53  ± 0.33  5.31 ± 0.30 5.28 ± 0.25 5.22 ± 0.21 
TG (mmol·L-1) 1.11 ± 0.22 1.11 ± 0.22 1.34 ± 0.30  1.03 ± 0.22 1.03 ± 0.19 1.02 ± 0.19  0.92 ± 0.13 0.74 ± 0.11 0.89 ± 0.13 
HDL-c (mmol·L-1) 1.40 ± 0.16 1.37 ± 0.14 1.33 ± 0.13  1.65 ± 0.16 1.68 ± 0.17 1.73 ± 0.19  1.75 ± 0.15 1.82 ± 0.18 1.76 ± 0.14 
LDL-c (mmol·L-1) 3.13 ± 0.26 3.17 ± 0.20 3.20 ± 0.16  3.04 ± 0.19 3.19 ± 0.19 3.34 ± 0.22  3.42 ± 0.28 3.12 ± 0.26 3.04 ± 0.25 
PL = placebo; dGTE = decaffeinated green tea extract; dGTE+ = decaffeinated green tea extract with antioxidants. %B = Homeostasis Model Assessment (HOMA2) steady state beta cell 
function %; %S = HOMA2 insulin sensitivity %; HOMA-IR = HOMA2 insulin resistance; FFA = free fatty acids; CholTOT = total cholesterol; TG = triglycerides; HDL-c = high-density 
lipoprotein cholesterol; LDL-c = low-density lipoprotein cholesterol. * significantly different to PL at timepoint (p ≤ 0.049).
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Table 8 Normalised mean fold change in serum cardio-metabolic markers by week 4 (NΔ0−4), and week 8 (NΔ0−8). 
 NΔ0–4 NΔ0–8 
Variable PL dGTE dGTE+ PL dGTE dGTE+ 
Glucose (mmol·L−1) +0.00 ± 0.02 −0.04 ± 0.03 +0.00 ± 0.02 +0.01 ± 0.02 −0.04 ± 0.02 −0.02 ± 0.02 
Insulin (pmol·L−1) +0.28 ± 0.24 +0.03 ± 0.08 +0.22 ± 0.12 +0.45 ± 0.34 -0.04 ± 0.12 +0.06 ± 0.10 
%B +0.08 ± 0.09 +0.12 ± 0.08 +0.18 ± 0.08 +0.13 ± 0.12 +0.05 ± 0.07 +0.11 ± 0.07 
%S +0.01 ± 0.15 +0.03 ± 0.08 −0.16 ± 0.06 −0.07 ± 0.13 +0.16 ± 0.15 −0.05 ± 0.07 
HOMA-IR +0.17 ± 0.16 +0.02 ± 0.08 +0.26 ± 0.10 +0.29 ± 0.21 −0.02 ± 0.12 +0.09 ± 0.08 
Leptin (ng·mL−1) +0.13 ± 0.20 −0.02 ± 0.07 +0.00 ± 0.09 +0.26 ± 0.13 +0.02 ± 0.08 +0.02 ± 0.11 
Adiponectin (µg·mL−1) −0.02 ± 0.01 −0.03 ± 0.05 +0.05 ± 0.04 +0.01 ± 0.05 +0.02 ± 0.04 -0.02 ± 0.04 
Glycerol (µmol·L−1) +0.15 ± 0.15 +0.33 ± 0.16 +0.20 ± 0.24 +0.11 ± 0.09 +0.11 ± 0.14 +0.22 ± 0.23 
FFA (µmol·L−1) +0.00 ± 0.12 +0.27 ± 0.08 +0.21 ± 0.18 +0.08 ± 0.18 +0.22 ± 0.20 +0.17 ± 0.22 
CholTOT (mmol·L−1) +0.00 ± 0.02 +0.04 ± 0.03 +0.00 ± 0.03 +0.03 ± 0.03 +0.07 ± 0.03 −0.01 ± 0.02 
TG (mmol·L−1) +0.03 ± 0.11 +0.05 ± 0.11 −0.15 ± 0.11 +0.19 ± 0.16 +0.02 ± 0.09 −0.03 ± 0.06 
HDL-c (mmol·L−1) −0.01 ± 0.04 +0.02 ± 0.03 +0.04 ± 0.04 −0.03 ± 0.04 +0.04 ± 0.03 +0.01 ± 0.04 
LDL-c (mmol·L−1) +0.03 ± 0.04 +0.05 ± 0.03 −0.07 ± 0.06 +0.05 ± 0.06 +0.10 ± 0.04 −0.09 ± 0.06 * 
PL = placebo; dGTE = decaffeinated green tea extract; dGTE+ = decaffeinated green tea extract with antioxidants. * denotes 
significantly different to dGTE (p = 0.038).
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Table 9. Mean serum liver function markers at baseline (week 0), week 4 and 8 between intervention groups. 
 PL  dGTE  dGTE+ 
Variable Baseline Week 4 Week 8  Baseline Week 4 Week 8  Baseline Week 4 Week 8 
ALT (U·L-1) 56.89 ± 23.14 47.22 ± 15.86 40.67 ± 11.72  34.56 ± 2.69 28.89 ± 1.62 34.22  ± 2.41  28.33 ± 1.41 30.78 ± 1.82 31.33 ± 1.85 
AST (U·L-1) 28.33 ± 10.70 37.11 ± 15.58 20.11 ± 3.51  19.78 ± 1.23 17.11 ± 1.62 21.11 ± 1.35  19.11 ± 2.12 18.22 ± 1.42 19.33 ± 1.27 
ALP (U·L-1) 66.89 ± 7.13* 65.22 ± 5.96* 60.22 ± 6.15  60.11 ± 3.36 60.00 ± 3.76 59.00 ± 4.20  59.44 ± 3.70 60.67 ± 4.18 56.67 ± 3.82 
Bilirubin (µmol·L-1) 10.78 ± 2.26 9.33 ± 1.80 9.89 ± 1.14  9.67 ± 0.94 9.89 ± 0.92 10.00 ± 1.04  7.78 ± 0.81 7.56 ± 0.87 8.44 ± 0.67 
PL = placebo; dGTE = decaffeinated green tea extract; dGTE+ = decaffeinated green tea extract with antioxidants. ALT = alanine aminotransferase; AST = aspartate transaminase; ALP = 
alkaline phosphatase. * significantly different to week 8 within group (p ≤ 0.025).
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Table 10. Normalised mean fold change in serum liver function markers by week 4 (NΔ0−4), and week 8 (NΔ0−8). 
 NΔ0−4 NΔ0−8 
Variable PL dGTE dGTE+ PL dGTE dGTE+ 
ALT (U·L−1) −0.06 ± 0.12 −0.15 ± 0.04 +0.11 ± 0.10 −0.15 ± 0.06 +0.01 ± 0.06 +0.11 ± 0.07 * 
AST (U·L−1) +0.49 ± 0.62 −0.12 ± 0.09 +0.02 ± 0.11 −0.09 ± 0.10 +0.08 ± 0.05 +0.10 ± 0.12 
ALP (U·L−1) −0.01 ± 0.02 +0.00 ± 0.03 +0.02 ± 0.02 −0.09 ± 0.04 −0.02 ± 0.03 −0.05 ± 0.02 
Bilirubin (µmol·L−1) −0.02 ± 0.14 +0.07 ± 0.13 +0.02 ± 0.11 +0.08 ± 0.15 +0.09 ± 0.15 +0.14 ± 0.09 
PL = placebo; dGTE = decaffeinated green tea extract; dGTE+ = decaffeinated green tea extract with antioxidants. * denotes 
significantly different to PL (p = 0.015). 
4. Discussion 
This study aimed to assess the longer-term impact of moderate dGTE supplementa-
tion (with or without antioxidant nutrients) on fat oxidation, body composition and car-
dio-metabolic risk factors in overweight, but healthy individuals engaged in regular exer-
cise. The findings from the current study demonstrated that a moderate dose of dGTE 
consumed over 8 weeks did not result in a statistically significant change on fat oxidation 
rates, but did produce a non-significant increase in both MFO (+12.7%) and relative MFO 
(+13.9%). In contrast, the use of a novel dGTE+ formula, containing antioxidants in addi-
tion to dGTE, had a significant impact (moderate–large effect size) on MFO (+45.5%) and 
relative MFO (+49.4%) by week 8 of supplementation in recreationally active, overweight 
individuals. Additionally, a large effect size for FATMIN (+22.5%) was observed with 
dGTE+ over the last 4 weeks of this study. Metabolic changes were also observed by week 
8 for dGTE+, with a large effect size reported for improvements in steady state substrate 
utilisation, evidenced by lower mean RER (-5.3%), improved relative FATOX (+55.2%) and 
increased the contribution of fat to total EE (+64.8%). Collectively, these findings suggest 
that a novel dGTE+ formula positively influenced fat oxidation in overweight individuals, 
particularly in the final 4 weeks of this study. 
With regards to the methodological approaches to FATOX measures, concerns have 
been noted in the literature pertinent to reliability and variability [53–55]. This was also 
observed in the current study with dGTE+ improving steady state FATOX by +28.4%, which 
was comparable to previous work undertaken [25], despite being non-significant. Whilst 
mean MFO and steady state FATOX rates in the current study were comparable to previous 
research with untrained [56], active [57–59] or overweight individuals [58,60–62], a large 
inter-individual range was noted (MFO range: 26–353 mg·min−1). As such, normalised 
data were also assessed to confirm or support findings. When data were normalised, tak-
ing into consideration individual responses to the intervention, MFO, relative MFO and 
FATMIN were all significantly enhanced with dGTE+ overall compared with PL, but not 
dGTE. However, for steady state exercise, normalised data only confirmed improved sub-
strate utilisation for dGTE+ based on a reduced RER and the contribution of carbohydrate 
to total EE compared with dGTE. Whilst this further supports the contention that dGTE+ 
improved fat oxidation dynamics and substrate utilisation efficiency, data should be in-
terpreted with caution based on individual ‘responders’ to the protocol. Overall FATMAX 
was not improved with dGTE+, despite a +24% increase in the latter 4 weeks of this study. 
This may be explained with the wide range of FATMAX values observed across this study 
(range: 24.1 to 52.4%VO2peak). 
Previous studies have reported mixed findings on the effect of GTE on fat oxidation, 
with several observing improvements in whole-body fat oxidation rates (+17–35% im-
provement employing a dose range of 270−400 mg·d−1 EGCG) [11,17–19,25] and no or 
small effects elsewhere (<+5−7% improvement with a dose range of 180–624 mg·d−1 EGCG) 
[21–24,26,63]. Indeed, a recent meta-analysis [64] highlighted a non-significant effect of 
EGCG supplementation on fat oxidation when compared with placebo (mean difference: 
210 mg·min-1), although these findings were based on pooled data from only two random-
ised controlled trials and should be interpreted with caution. Interestingly, beneficial 
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effects of GTE have been mainly observed with healthy, active, untrained or sedentary 
individuals using acute (<2 days) moderate EGCG dose [11,17–19]. However, within these 
studies, it is unclear whether enhanced fat oxidation was due to accumulated GTE intake 
or dose consumed prior to exercise testing considering plasma EGCG concentrations peak 
at ~90 mins, with a reported half-life of ~10 hours [65,66]. It is further unclear whether 
these short-term studies have meaningful impact in the longer term. Chronic intake of 
dGTE, with comparable EGCG dose, but not consumed on the day of testing, has been 
shown to enhance fat oxidation and exercise performance in healthy, recreationally active 
males [25]. However, the use of dGTE has been disputed elsewhere [26] with physically 
active males, and appears to offer little benefit to trained individuals in terms of substrate 
utilisation and/or endurance exercise performance [21–24]. 
Collectively, these studies indicate that EGCG (both caffeinated and decaffeinated) 
may be effective in recreationally active or less trained individuals, potentially via ther-
mogenic mechanisms pertinent to COMT inhibition and increased lipolytic activity lead-
ing to enhanced FATOX during exercise [9,14], although supporting evidence to confirm 
this is currently lacking. In the current study, it is noteworthy that normalised FFAs were 
greater for both dGTE groups compared with PL, albeit non-significantly. In the longer 
term, the effectiveness of this mechanism may be related to COMT genotype [67] and/or 
specific adaptations in mitochondrial efficiency with regular EGCG consumption (partic-
ularly when coupled with exercise training). It has been proposed that EGCG consump-
tion may act in a ‘calorie-restriction-mimetic’ manner through AMPK and sirtuin path-
ways. This may further modulate PGC1α, peroxisome proliferator-activated receptors 
(PPARs) and Forkhead box O (FOXO) gene expression, particularly in liver, adipose and 
skeletal muscle tissue [14,15,68]. However, this has been disputed elsewhere in animal 
studies, with inference that adaptations in fatty acid translocase/CD36mRNA are more 
likely associated with improvements in fat oxidation [69]. Future studies should aim to 
explore underlying mechanisms pertinent to fat metabolism gene expression, β-oxidation 
enzymes and fatty acid transporters following regular EGCG consumption. Further atten-
tion towards EGCG dose, as well as the effects of other potential calorie-restriction-mi-
metic nutrients (e.g., resveratrol, LA, curcumin, and other plant polyphenols [i.e., gallic 
acid]) on mitochondrial efficiency are also warranted. 
In the current study, the specific use of dGTE did not significantly enhance fat oxida-
tion measures in agreement with previous research [21,22,26,63]. However, the use of a 
novel dGTE+ formula does support findings particularly pertinent to less trained and/or 
overweight individuals [11,17,19]. The inclusion of quercetin within the dGTE+ may have 
reduced degradation or oxidation of EGCG within the small intestine (especially consid-
ering dietary quercetin intakes were consistent between groups across the intervention). 
It has been suggested that this could enhance EGCG bioavailability either directly, or 
through increased EGCG delivery to the large intestine, microbiota conversion to EGCG 
ring-fission metabolites and phenolic compounds, and subsequent elevated plasma free 
and conjugated forms of EGCG [31,32,65,70]. Additionally, the increased bioavailability 
of quercetin, even at a low dose may have supported antioxidant mechanisms of EGCG 
pertinent to longer-term mitochondria efficiency [70]. 
The additional inclusion of LA in the dGTE+ formula may have also enhanced EGCG 
stability through local antioxidant mechanisms, leading to increased EGCG availability. 
However, as EGCG bioavailability was not ascertained in the current study, this cannot 
be confirmed. As the use of dGTE only did not significantly influence FATOX, it is feasible 
the observed metabolic benefits associated with dGTE+ may be specific to LA. Whilst nu-
merous mechanisms have been proposed, LA supports mitochondrial efficiency as a co-
factor for α-ketoacid dehydrogenases [71]. Reduced LA (DHLA) has also been implicated 
as a powerful natural antioxidant, highlighting that LA may support endogenous antiox-
idant status and mitochondrial protection [71–73]. Additionally, LA has been proposed to 
influence AMPK pathways which may modulate muscle glucose uptake via GLUT4 trans-
location, and insulin sensitivity [71,72]. Therefore, in the longer term, it is feasible that, 
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coupled with regular exercise training, LA could support enhanced mitochondrial effi-
ciency, FATOX and subsequent weight loss. However, whilst a recent meta-analysis sup-
ports the contention that LA may elicit small, meaningful weight reduction benefits, stud-
ies ranging from 8–52 weeks have employed higher LA doses between 300 and 1800 
mg·d−1 [74], which may explain such findings. As a lower dose of LA was employed in the 
current study, it is proposed that the synergistic inclusion of LA and quercetin may have 
acted to enhance EGCG bioavailability leading to up-regulated fat oxidation pathways in 
addition to regular exercise. Further research is warranted to confirm EGCG bioavailabil-
ity with synergistic inclusion of quercetin and/or LA, along with cellular mechanistic 
pathways, particularly considering higher doses commonly used in commercial formulas. 
Whilst the use of dGTE+ impacted on fat oxidation, by the end of the intervention, 
neither dGTE supplementation influenced overall body composition measures. This was 
despite relative, albeit small reductions in overall mean body mass (−0.50 kg), body fat 
percentage (−0.50%), fat mass (−0.37 kg), abdominal circumference (−0.77 cm) or SAD 
(−0.61 cm), particularly for dGTE+ compared with PL. Furthermore, the relative reduction 
in estimated VFA with dGTE+ was ~3-fold greater than for both dGTE and PL, albeit non-
significant. Maintenance of habitual exercise only marginally impacted on body compo-
sition indices as evidenced by a significant reduction in waist and abdomen circumference 
for PL and dGTE at week 4 within group only. Collectively, the results indicate that when 
habitual exercise and dietary intake are controlled for, dGTE supplementation did not 
favour improved body composition indices. As dGTE+ only enhanced FATOX by week 8, 
any changes in body composition attributed to EGCG mechanisms may require longer 
interventions based on overall relative patterns in body composition indices with dGTE+. 
Indeed, a previous meta-analysis [9] highlighted that GT consumption across studies ex-
ceeding 12 weeks resulted in a small, positive effect on body mass loss (−1.31 kg), with 
greater effects (−1.60 kg) observed for low habitual caffeine intake users. 
However, the lack of efficacy of dGTE to modify body composition measures does 
concur with other longer-term studies (EGCG dose: 199–843 mg·d−1) [28,67,75], although 
physical activity was only partially monitored in these studies, and one study [28] also 
introduced a low energy diet as part of the intervention. Elsewhere, significant improve-
ments in body composition have been reported with GTE consumption (EGCG dose: 100–
225 mg·d−1) [12,13,29], particularly when combined with an exercise intervention in previ-
ously sedentary individuals [12,29]. Interestingly, in one study [29] exercise prescription 
began at 40% HR reserve (HRR) and progressed up to 50-59% HRR. Other studies utilising 
training at FATMAX (range:~34–52%VO2max [62,76,77]) in overweight, obese or diabetic 
women demonstrated significant improvements in body mass, BMI, fat mass and visceral 
trunk fat. In the current study, physical activity guidelines (>150 mins·wk−1 at a moderate 
intensity ~60–65%VO2peak in line with other studies [18,78]) were maintained. As this in-
tensity was above participants’ FATMAX, this likely favoured carbohydrate metabolism 
and, in part, may explain the small decrease in MFO observed with PL. Combining dGTE+ 
with individualised FATMAX training in overweight individuals may therefore favourably 
improve body composition, warranting further research.  
Cardio-metabolic variables were largely unaffected by either dGTE supplementation, 
with the exception of a medium effect size reported for LDL-c which was ~11% lower with 
dGTE+ by week 8, and further supported via normalised values. The relative reduction in 
total LDL-c across the intervention with dGTE+ (−0.38 ± 0.22 mmol·L-1) was comparable to 
previous studies [5,79], which may be important as the mean values were considered ele-
vated. This concurs with a recent meta-analysis indicating that LDL-c is likely reduced 
with regular green tea consumption (all sources) by −0.12 mmol·L-1 [80], and likely further 
reduced (−0.14 mmol·L-1) when capsulated or decaffeinated green tea products are used 
[80]. Interestingly, the observed effects of green tea consumption (all sources) appear 
greater over time, with noted reductions for total cholesterol (−0.14 mmol·L-1) and triglyc-
erides (−0.23 mmol·L-1) in longer-term clinical trials (> 12 weeks) [80]. In the current study, 
as cholesterol biomarkers were largely unaffected with dGTE alone, this infers that the 
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observed reductions in LDL-c with dGTE+ may have been attributed to either increased 
bioavailability via inclusion of low-dose quercetin, or separately via the inclusion of LA 
acting independently. Indeed, other reviews [81] have reported significant reductions in 
LDL-c of −0.33 mmol·L-1 with LA alone, which is comparable to that observed in the cur-
rent study.  
Both leptin and adiponectin levels were unaffected across the intervention with 
dGTE or dGTE+. This agrees with a recent meta-analysis [82] demonstrating that leptin 
concentration is likely unaffected with GT (from all sources) when consumed for less than 
12 weeks. In contrast, longer-term use of GT (>12 weeks) likely increases leptin concentra-
tions (effect size: 2.90 [82]). As appetite hormones and body composition changes were 
largely unaffected by either dGTE in the current study, this suggests that observed bene-
fits of dGTE+ on fat oxidation by week 8 may have been attributed to gene expression 
associated with mitochondrial efficiency [14]. It is noteworthy that adiponectin levels 
were significantly higher with dGTE+ compared to PL at baseline, week 4 and 8. Adi-
ponectin has been associated with synergistic activation of AMPK, p38 mitogen-activated 
protein kinase (MAPK) and PPARα in skeletal muscle, and hence fatty acid oxidation [83]. 
Higher adiponectin levels, combined with dGTE+, may have favourably altered AMPK 
kinetics, resulting in enhanced mitochondrial fatty acid oxidation across the intervention. 
In accordance with previous reviews [82], it is feasible that longer-term dGTE consump-
tion further influences appetite regulation favouring improved body composition charac-
teristics, especially when combined with enhanced fat metabolism.  
It is also noteworthy, when considering normalised values, that mean insulin, 
HOMA-IR and leptin changes were elevated with PL across the intervention (albeit non-
significantly), with negligible changes observed for dGTE or dGTE+. It is therefore unclear 
whether the small changes observed for PL were related to dietary composition differ-
ences, or whether dGTE acted in a ‘protective’ manner. However, collectively, these re-
sults support previous findings that GTE was ineffective in improving cardio-metabolic 
function [6,27,28], but differ from other studies where positive effects of GTE have been 
observed with [30] or without exercise [5,13]. Interestingly, one other study [84] employed 
a theaflavin-enriched GTE strategy, resulting in significant reductions in LDL-c and total 
cholesterol. This combination was proposed to reduce intestinal absorption and/or in-
creased excretion of cholesterol, as well as LDL-c liver receptor up-regulation. The com-
bined use of quercetin and LA with dGTE+ in the current study may have similarly en-
hanced dGTE effectiveness.  
Whilst dGTE+ also resulted in a significant reduction in resting HR by week 4 com-
pared to dGTE, but not by week 8, this did not impact on blood pressure measurements. 
This is somewhat surprising as a recent meta-analysis on green tea (from all sources) high-
lighted studies (≤12 weeks) resulting in a reduction of −1.32 mmHg for SBP (non-signifi-
cant) and -1.78 mmHg for DBP (deemed significant), with lower observed effects for cap-
sulated green tea, and green tea (all sources) consumed over longer periods (> 12 weeks) 
[85]. In the current study, dGTE+ resulted in a reduction of −3.33 mmHg (for SBP) and -
1.78 mmHg (for DBP), which exceeded the observed reduction expected for exercise/pla-
cebo (−2.44 mmHg for SBP and −0.78 mmHg for DBP), but was deemed non-significant. 
Whilst this may be partly explained by inter-individual variance in blood pressure re-
sponses, our results suggest that decaffeinated green tea extract did not impact on blood 
pressure response above that expected through maintenance of regular exercise.  
An important aspect of the current study was the inclusion of liver enzyme and bili-
rubin measures. This was undertaken based on current concerns with the potential for 
GTE-induced hepatotoxicity [86]. However, no significant elevations were observed for 
any measures, indicating relative safety of dGTE at a moderate dose across the interven-
tion period. Whilst it has been noted that fasted intake may be a contributing factor to 
GTE-induced heptatoxicity [87], other studies have highlighted the potential for reduced 
bioavailability when GTE is consumed with food [20]. In the current study, participants 
were requested to consume dGTE away from food in a split-dose manner. As such, it is 
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possible that consumption may have occurred in an absorptive state. Coupled with a 
lower single dose per consumption (i.e., 200 mg EGCG per capsule), this may, in part, 
explain normal liver function observed in the current study. Whilst this supports previous 
research [6], and is in line with current recommendations [87,88], the efficacy of lower 
doses is warranted, as well as awareness of product composition. As example, un-
published data from our laboratory indicate that exposure to the specific dGTE used in 
this study impacts AMPK activity and mitochondrial oxidative stress to improve survival 
of hepatocytes in vitro. Therefore, due consideration of the effect of dGTE on oxidative 
stress pathways at a cellular level is also needed to understand the molecular mechanisms 
impacting MFO, as other products may differ in terms of biological effects.   
It is important to note several limitations of the current study. As previously men-
tioned, EGCG bioavailability was not undertaken, and as no LA-specific intervention was 
included, findings should be interpreted with caution. Further studies investigating the 
specific effects of LA with or without dGTE are therefore warranted. In the current study 
a standardised dGTE (70% EGCG) product was sourced based on our previous research 
[25]. Whilst this was independently verified, the content of other catechins (e.g., (−)-epi-
catechin-3-gallate (ECG)), flavonols (e.g., isoquercitin), flavonol glycosides and their agly-
cones, were not quantified. Whilst EGCG is the most abundant catechin within dGTE, the 
remaining catechin/flavonol compounds may have contributed to findings. Consideration 
to the presence, and biological activity, of other catechins/flavonols within dGTE supple-
mentation is therefore warranted in future research.  
In a similar context, consideration to dietary consistency and total polyphenol intake 
is also warranted. In the present study, relative dietary intake consistency was established 
in the 7 day period leading into each testing session. Furthermore, estimated quercetin 
intake (overall mean: 20.6 ± 8.5 mg·d-1) was comparable between groups, and similar to 
previously reported research [89,90]. Therefore, any influence of the dGTE+ compound 
may have related to the enhanced bioavailability of EGCG with additional quercetin. 
However, it is feasible that individual dietary variance and total polyphenol intake out-
side of collection periods may have limited findings. Future research should therefore 
consider the impact of dGTE strategies in conjunction with low or high dietary polyphenol 
intake when combined with exercise strategies. Similarly, whilst exercise was monitored 
across the full intervention period, we did not investigate other components of physical 
activity such as non-exercise activity thermogenesis or sedentary periods which could af-
fect overall metabolic flexibility and/or fat oxidation, as previously reported [91,92], even 
when physical activity guidelines are met. Finally, although testing sessions were stand-
ardised, as the majority of the participants were females, it is feasible that hormonal vari-
ance pertinent to menstrual cycle regulation may have influenced metabolic changes. 
However, this has been disputed elsewhere [93]. 
5. Conclusions 
The use of a novel dGTE+ (containing quercetin and LA) was effective in improving 
MFO and FATMIN in healthy, overweight individuals by week 8 of the intervention. This 
corresponded with improved FATOX during steady state exercise and the reduced contri-
bution of carbohydrate to total energy expenditure. However, when habitual exercise and 
dietary intake are maintained, this did not translate to improved body composition or 
markers of cardio-metabolic health, with the exception of reduced LDL-c. Future studies 
investigating dose–response and longer-term implications of dGTE+, particularly in com-
bination with dietary strategies to support weight-loss in overweight individuals are war-
ranted. 
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